Nagai Moritaka, Watanabe Masatoshi, Iwase Teruhiko, Yamao Kenji, Isaji Shuji
First Department of Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu-shi, Mie 514-8507, Japan.
World J Surg. 2002 Jan;26(1):91-8. doi: 10.1007/s00268-001-0187-0. Epub 2001 Nov 26.
We analyzed clinical features and genetic alterations in the noncancerous and cancerous biliary lesions obtained from pancreaticobiliary maljunction (PBM) patients. Gallbladder (GB) and bile duct (BD) lesions were obtained surgically from 36 patients with PBM, and polymerase chain reaction (PCR) methods were used to examine for mutations of the K-ras gene and the p53 gene and for microsatellite instability (MSI). The 36 cases were clinically classified into two types according to whether extrahepatic bile duct dilatation was present: a congenital choledochal dilatation (CCD) group (n = 20) and a noncongenital choledochal dilatation (NCCD) group (n = 16). In the NCCD group, all 16 GB specimens exhibited hyperplastic, dysplastic, and cancerous (n = 9) lesions, but no pathological lesions were detected in the 12 BD specimens. On the other hand, in the CCD group, pathological examination revealed lesions, including 8 cancerous lesions, in 60% of the 20 GB specimens and lesions, and including 8 cancerous lesions, in 65% of the 20 BD specimens. K-ras mutations and MSI were detected in 33.3% and 0%, respectively, of 9 hyperplastic lesions, 28.6% and 85.7%, respectively, of 7 dysplastic lesions, and 60.0% and 80.0%, respectively, of 25 cancerous lesions (p <0.05; MSI in hyperplasia vs. dysplasia and cancer). There was no difference of the frequency in K-ras mutations and MSI between the NCCD and CCD groups. By contrast, p53 mutations were detected only in the cancerous GB lesions of both types, the rate being 35.3%. Genetic alterations of K-ras, MSI, and p53 are strongly associated with biliary tract cancer in PBM patients. MSI appears to contribute to carcinogenesis in the biliary tract mucosa of PBM patients, and p53 mutations may be related to the development of GB cancer in the CCD group.
我们分析了胰胆管合流异常(PBM)患者非癌性和癌性胆管病变的临床特征及基因改变。从36例PBM患者手术获取胆囊(GB)和胆管(BD)病变组织,采用聚合酶链反应(PCR)方法检测K-ras基因和p53基因的突变以及微卫星不稳定性(MSI)。根据肝外胆管是否扩张,将36例患者临床分为两型:先天性胆总管扩张(CCD)组(n = 20)和非先天性胆总管扩张(NCCD)组(n = 16)。在NCCD组中,16例GB标本均呈现增生、发育异常及癌性(n = 9)病变,但12例BD标本未检测到病理病变。另一方面,在CCD组中,病理检查显示,20例GB标本中有60%存在病变,包括8例癌性病变;20例BD标本中有65%存在病变,包括8例癌性病变。在9例增生性病变中,K-ras突变和MSI的检出率分别为33.3%和0%;在7例发育异常性病变中,分别为28.6%和85.7%;在25例癌性病变中,分别为60.0%和80.0%(p<0.05;增生与发育异常及癌中的MSI)。NCCD组和CCD组之间K-ras突变和MSI的频率无差异。相比之下,仅在两型的癌性GB病变中检测到p53突变,发生率为35.3%。K-ras、MSI和p53的基因改变与PBM患者的胆管癌密切相关。MSI似乎在PBM患者胆管黏膜的致癌过程中起作用,p53突变可能与CCD组GB癌的发生有关。